DNA repair deficiency and the immune microenvironment: A pathways perspective

Friedberg, 2003, DNA damage and repair, Nature, 421, 436, 10.1038/nature01408 Hakem, 2008, DNA-damage repair; the good, the bad, and the ugly, EMBO J., 27, 589, 10.1038/emboj.2008.15 Jackson, 2009, The DNA-damage response in human biology and disease, Nature, 461, 1071, 10.1038/nature08467 Concannon, 2023, Combining targeted DNA repair inhibition and immune-oncology approaches for enhanced tumor control, Mol. Cell, 83, 660, 10.1016/j.molcel.2022.12.031 Krokan, 2013, Base excision repair, Cold Spring Harb. Perspect. Biol., 5, a012583, 10.1101/cshperspect.a012583 Caldecott, 2014, DNA single-strand break repair, Exp. Cell Res, 329, 2, 10.1016/j.yexcr.2014.08.027 Jiricny, 2013, Postreplicative mismatch repair, Cold Spring Harb. Perspect. Biol., 5, a012633, 10.1101/cshperspect.a012633 Jiricny, 2006, The multifaceted mismatch-repair system, Nat. Rev. Mol. Cell Biol., 7, 335, 10.1038/nrm1907 Ceccaldi, 2016, The Fanconi anaemia pathway: new players and new functions, Nat. Rev. Mol. Cell Biol., 17, 337, 10.1038/nrm.2016.48 Ma, 2018, The therapeutic significance of mutational signatures from DNA repair deficiency in cancer, Nat. Commun., 9, 10.1038/s41467-018-05228-y Black, 2019, Molecular basis of microhomology-mediated end-joining by purified full-length Poltheta, Nat. Commun., 10, 10.1038/s41467-019-12272-9 Stinson, 2021, Repair of DNA double-strand breaks by the nonhomologous end joining pathway, Annu. Rev. Biochem., 90, 137, 10.1146/annurev-biochem-080320-110356 Yang, 2018, Translesion and repair DNA polymerases: diverse structure and mechanism, Annu. Rev. Biochem., 87, 239, 10.1146/annurev-biochem-062917-012405 Knijnenburg, 2018, Genomic and molecular landscape of dna damage repair deficiency across the cancer genome atlas, Cell Rep., 23, 239, 10.1016/j.celrep.2018.03.076 Turner, 2004, Hallmarks of 'BRCAness' in sporadic cancers, Nat. Rev. Cancer, 4, 814, 10.1038/nrc1457 Miki, 1994, A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1, Science, 266, 66, 10.1126/science.7545954 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Alexandrov, 2013, Signatures of mutational processes in human cancer, Nature, 500, 415, 10.1038/nature12477 Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445 Bryant, 2005, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 913, 10.1038/nature03443 Marin-Acevedo, 2018, Next generation of immune checkpoint therapy in cancer: new developments and challenges, J. Hematol. Oncol., 11, 10.1186/s13045-018-0582-8 Kroemer, 2013, Immunogenic cell death in cancer therapy, Annu Rev. Immunol., 31, 51, 10.1146/annurev-immunol-032712-100008 Richman, 2015, Deficient mismatch repair: read all about it (review), Int J. Oncol., 47, 1189, 10.3892/ijo.2015.3119 Hewish, 2010, Mismatch repair deficient colorectal cancer in the era of personalized treatment, Nat. Rev. Clin. Oncol., 7, 197, 10.1038/nrclinonc.2010.18 Zhao, 2014, Mismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks, Elife, 3, 10.7554/eLife.02725 Germano, 2018, The clinical impact of the genomic landscape of mismatch repair-deficient cancers, Cancer Discov., 8, 1518, 10.1158/2159-8290.CD-18-0150 Woerner, 2015, Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors, Mol. Carcinog., 54, 1376, 10.1002/mc.22213 Germano, 2017, Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth, Nature, 552, 116, 10.1038/nature24673 Cortes-Ciriano, 2017, A molecular portrait of microsatellite instability across multiple cancers, Nat. Commun., 8, 10.1038/ncomms15180 Boland, 1998, A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer, Cancer Res, 58, 5248 Beamer, 2012, Reflex immunohistochemistry and microsatellite instability testing of colorectal tumors for Lynch syndrome among US cancer programs and follow-up of abnormal results, J. Clin. Oncol., 30, 1058, 10.1200/JCO.2011.38.4719 Loukovaara, 2021, Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer, Cancer Med., 10, 1034, 10.1002/cam4.3691 Shia, 2008, Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry, J. Mol. Diagn., 10, 293, 10.2353/jmoldx.2008.080031 Streel, 2023, Diagnostic performance of immunohistochemistry compared to molecular techniques for microsatellite instability and p53 mutation detection in endometrial cancer, Int J. Mol. Sci., 24, 10.3390/ijms24054866 Dedeurwaerdere, 2021, Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer, Sci. Rep., 11, 10.1038/s41598-021-91974-x Stadler, 2016, Reliable detection of mismatch repair deficiency in colorectal cancers using mutational load in next-generation sequencing panels, J. Clin. Oncol., 34, 2141, 10.1200/JCO.2015.65.1067 Galon, 2006, Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 1960, 10.1126/science.1129139 Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov., 5, 43, 10.1158/2159-8290.CD-14-0863 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med, 372, 2509, 10.1056/NEJMoa1500596 Cercek, 2022, PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer, N. Engl. J. Med, 386, 2363, 10.1056/NEJMoa2201445 Mandal, 2019, Genetic diversity of tumors with mismatch repair deficiency influences anti-PD-1 immunotherapy response, Science, 364, 485, 10.1126/science.aau0447 Lu, 2021, DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity, Cancer Cell, 39, 96, 10.1016/j.ccell.2020.11.006 Kalbasi, 2020, Tumour-intrinsic resistance to immune checkpoint blockade, Nat. Rev. Immunol., 20, 25, 10.1038/s41577-019-0218-4 Guan, 2023, DNA mismatch repair in cancer immunotherapy, NAR Cancer, 5, 10.1093/narcan/zcad031 Rayner, 2016, A panoply of errors: polymerase proofreading domain mutations in cancer, Nat. Rev. Cancer, 16, 71, 10.1038/nrc.2015.12 Howitt, 2015, Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1, JAMA Oncol., 1, 1319, 10.1001/jamaoncol.2015.2151 Garmezy, 2022, Clinical and molecular characterization of POLE mutations as predictive biomarkers of response to immune checkpoint inhibitors in advanced cancers, JCO Precis Oncol., 10.1200/PO.21.00267 Xing, 2022, Polymerase epsilon-associated ultramutagenesis in cancer, Cancers, 14, 10.3390/cancers14061467 Krejci, 2012, Homologous recombination and its regulation, Nucleic Acids Res., 40, 5795, 10.1093/nar/gks270 Lord, 2016, BRCAness revisited, Nat. Rev. Cancer, 16, 110, 10.1038/nrc.2015.21 Abkevich, 2012, Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer, Br. J. Cancer, 107, 1776, 10.1038/bjc.2012.451 Popova, 2012, Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation, Cancer Res, 72, 5454, 10.1158/0008-5472.CAN-12-1470 Birkbak, 2012, Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents, Cancer Discov., 2, 366, 10.1158/2159-8290.CD-11-0206 Telli, 2016, Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer, Clin. Cancer Res., 22, 3764, 10.1158/1078-0432.CCR-15-2477 Pellegrino, 2020, Homologous recombination repair deficiency and the immune response in breast cancer: a literature review, Transl. Oncol., 13, 410, 10.1016/j.tranon.2019.10.010 Samstein, 2021, Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy, Nat. Cancer, 1, 1188, 10.1038/s43018-020-00139-8 Strickland, 2016, Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer, Oncotarget, 7, 13587, 10.18632/oncotarget.7277 Tie, 2022, Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets, J. Hematol. Oncol., 15, 10.1186/s13045-022-01282-8 Pantelidou, 2019, PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer, Cancer Discov., 9, 722, 10.1158/2159-8290.CD-18-1218 Sato, 2019, Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: implications for precision medicine, Cancer Sci., 110, 3415, 10.1111/cas.14197 Patterson-Fortin, 2023, Polymerase theta inhibition activates the cGAS-STING pathway and cooperates with immune checkpoint blockade in models of BRCA-deficient cancer, Nat. Commun., 14 Scharer, 2013, Nucleotide excision repair in eukaryotes, Cold Spring Harb. Perspect. Biol., 5, a012609, 10.1101/cshperspect.a012609 Van Allen, 2014, Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma, Cancer Discov., 4, 1140, 10.1158/2159-8290.CD-14-0623 Permata, 2019, Base excision repair regulates PD-L1 expression in cancer cells, Oncogene, 38, 4452, 10.1038/s41388-019-0733-6 Volkova, 2020, Mutational signatures are jointly shaped by DNA damage and repair, Nat. Commun., 11, 2169, 10.1038/s41467-020-15912-7 Smith, 2010, The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer, Adv. Cancer Res., 108, 73, 10.1016/B978-0-12-380888-2.00003-0 Lanz, 2019, DNA damage kinase signaling: checkpoint and repair at 30 years, EMBO J., 38, 10.15252/embj.2019101801 Hallahan, 2019, ATM inhibition sensitizes tumors to high-dose irradiation, Cancer Res., 79, 704, 10.1158/0008-5472.CAN-18-4072 Pitter, 2021, Pathogenic ATM mutations in cancer and a genetic basis for radiotherapeutic efficacy, J. Natl. Cancer Inst., 113, 266, 10.1093/jnci/djaa095 Zhou, Y. et al. ATM Deficiency Confers Specific Therapeutic Vulnerabilities in Bladder Cancer. (under revision). Cleary, 2020, Biomarker-guided development of DNA repair inhibitors, Mol. Cell, 78, 1070, 10.1016/j.molcel.2020.04.035 Sato, 2017, DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells, Nat. Commun., 8, 10.1038/s41467-017-01883-9 Feng, 2020, ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways, EMBO J., 39, 10.15252/embj.2019104036